Clinical Trial Update: This Record Contains Information About the Mepolizumab Compassionate Use (CU) Product Activities: 104317: CU and Long-Term Access Study of Mepolizumab in HES. 201956:A Long-term Access Programme for Subjects With Severe Asthma 112562: Expanded Access for Patients With Hypereosinophilic

View source ↗

Summary

The document outlines compassionate-use and long-term access programs for mepolizumab in patients with hypereosinophilic syndrome, including expanded-access act…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypereosinophilic Syndrome

Drugs mentioned

• Mepolizumab (Nucala) (mepolizumab)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Hypereosinophilic Syndrome | Status: NO_LONGER_AVAILABLE